Author: Admin

Developer

Kratos Defense and Security Solutions (KTOS) – Wins $86 Million U.S. Army Contract

Posted on by Admin


Kratos Wins $86 Million, Assuming All Options Exercised, Single Award U.S. Army Contract for Drone Command and Control Systems

 

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a leading National Security Solutions provider and industry-leading provider of high-performance unmanned systems, today announced that Micro Systems, Inc., a wholly owned subsidiary of Kratos Defense & Security Solutions, Inc. and part of the Kratos Unmanned Systems Division, has received an $85,949,472 contract award, with a $60.7M base and two options totaling approximately $25.3M, from the U.S. Army to support the Army Ground Aerial Target Control System, including software updating, cyber security inspections and installation of replacement parts.

Steve Fendley, President of Kratos Unmanned Systems Division, said, “We are incredibly excited about this substantial win for the Unmanned Systems Division and for Kratos overall. This enables us to evolve, develop, and apply new technologies to the UAS / UGV command and control systems for the Army, which support development, testing, and training associated with our country’s defensive systems and military personnel. Our ground-based infrastructure capability, the foundation for this contract, is key to our overall unmanned vehicle strategy to design, develop, and produce the entire system. Kratos is fully committed to developing affordable technologies and proud that these systems are employed to enable our troops and defensive systems to remain at the highest level of capability and readiness.”

Micro Systems, Inc. has been the primary designer, manufacturer, and supplier of high-performance unmanned aerial and ground target command and control systems to the U.S. Department of Defense since 1985. These hardware and software systems have provided reliable and robust capability successfully supporting over 3,000 operational weapon system test, training, and evaluation missions worldwide. Advanced features enabling multi-domain multi-vehicle mission profiles, remote and autonomous control modes, high-speed high bandwidth datalink communications, and ensured integrity with rigorous cybersecurity and Information Assurance (IA) implementations have made Micro Systems, Inc. the premier target control system provider for aerial (subscale, full scale, and rotary wing), ground, seaborne, and small unmanned aerial system (sUAS) platforms.

Kratos Unmanned Systems Division is a leading provider of high performance unmanned aerial drone and target systems for threat representative target missions to exercise weapon, radar, and other systems; and tactical aerial drone systems for strike/ISR and force multiplication missions.

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology, and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information, please visit www.KratosDefense.com.

Notice Regarding Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687

[email protected]

Source: Kratos Defense & Security Solutions, Inc.

QuickChek – April 5, 2021

Posted on by Admin



Capstone Turbine CEO To Discuss Recent Revenue Growth Trends At The Upcoming Noble Capital Markets’ Virtual Road Show

Capstone Turbine announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for Tuesday, April 6, 2021

Research, News & Market Data on Capstone Turbine

Watch recent presentation from Capstone Turbine



Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean

Genprex announced that its Executive Vice President and Chief Operating Officer, Michael Redman, will present at the annual Cell & Gene Meeting on the Mediterranean

Research, News & Market Data on Genprex

Watch recent presentation from NobleCon17



electroCore, Inc. Announces Regulatory Approval in Canada

electroCore, Inc. announced that Health Canada has granted regulatory approval for the promotion and sale of the gammaCore Sapphire family of products in Canada

Research, News & Market Data on electroCore

Watch recent presentation from electroCore



Kratos Wins $86 Million Single Award U.S. Army Contract for Drone Command and Control Systems

Kratos Defense & Security Solutions announced that Micro Systems, Inc., a wholly owned subsidiary of Kratos Defense & Security Solutions has received an $85,949,472 contract award from the U.S. Army

Research, News & Market Data on Kratos Defense & Security Solutions

Watch recent presentation from Kratos



CanAlaska Uranium Change to Board

CanAlaska Uranium announced that Victor Fern has resigned from the CanAlaska Board

News & Market Data on CanAlaska Uranium

Stay up to date. Follow us:

CanAlaska Uranium (CVVUF)(CVV:CA) – CanAlaska Change to Board

Posted on by Admin


CanAlaska Change to Board
Victor Fern to go to new role with Cameco and Orano
CanAlaska address change

 

Vancouver, Canada, April 5, 2021 – CanAlaska Uranium Ltd.
(TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) (“CanAlaska” or the “Company”) reports that Victor Fern has resigned from the CanAlaska Board to pursue a new community role supporting Cameco and Orano’s operations in the Athabasca Basin. CanAlaska’s Management and Board of Directors wish Victor well in this new community role, and wishes to acknowledge the strong supporting role Victor has had with the direction of the Company’s activities since his appointment in 2008.

At the time of his appointment in March 2008 Mr Victor Fern was the immediate past Chief of the Fond du Lac Denesuline First Nation, at Fond du Lac, Saskatchewan. Mr Fern has been a longstanding member of the environmental monitoring committee for the Northern Athabasca area, and is involved with various private business interests in the Fond du Lac-Black Lake area. His extensive experience at uranium mining and milling operations in Northern Saskatchewan, and his 13 year tenure on the CanAlaska board makes him well suited to his new role as an advisor and educator in the community.

CanAlaska President, Peter Dasler, comments, “It has been a pleasure to work with Victor for the past 14 years, and to meet his friends and community. His new Community Liaison responsibilities for Cameco and Orano highlight how well regarded and knowledgeable is Victor. We can all learn a lot from each other, and I look forward to continuing our friendship and interactions in multiple matters into the future. Thank you Victor, best wishes from me and CanAlaska’s Board.”

Other News

 CanAlaska is moving to new offices in our current building. The new office address is Suite 580, 625 Howe Street, Vancouver, BC. V6C 2T6. This address will take effect May 1 2021.

About CanAlaska Uranium

 CanAlaska Uranium Ltd. (TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) holds interests in approximately 214,000 hectares (530,000 acres) in Canada’s Athabasca Basin – the “Saudi Arabia of Uranium.” CanAlaska’s strategic holdings have attracted major international mining companies. CanAlaska is currently working with Cameco and Denison at two of the Company’s properties in the Eastern Athabasca Basin. CanAlaska is a project generator positioned for discovery success in the world’s richest uranium district. The Company also holds properties prospective for nickel, copper, gold and diamonds. For further information visit www.canalaska.com.

The qualified technical person for this news release is Dr Karl Schimann, P. Geo, CanAlaska director and VP Exploration.

 

On behalf of the Board of Directors

 

“Peter Dasler”

Peter Dasler, M.Sc., P.Geo.

President & CEO

CanAlaska Uranium Ltd.

 

Contacts:

 

Peter Dasler, President

Tel: +1.604.688.3211 x 138

Email: [email protected]

 

Cory Belyk, COO

Tel: +1.604.688.3211 x 138

Email: [email protected]

 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.  

 Forward-looking information

 All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Source: CanAlaska Uranium Ltd.

electroCore Inc. (ECOR) – Announces Regulatory Approval in Canada

Posted on by Admin


electroCore, Inc. Announces Regulatory Approval in Canada

 

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that 
Health Canada has granted regulatory approval for the promotion and sale of the gammaCore Sapphire family of products in 
Canada for prevention and therapeutic treatment of migraine and cluster headache, as outlined in the registration application with 
Health Canada.

gammaCore Sapphire will be distributed in 
Canada by 
RSK Medical Inc., pursuant to an exclusive distribution agreement announced on 
January 26, 2021. The initial term of the agreement is three years, and the agreement contains customary terms and conditions, including minimum purchase commitments. “Patients and clinicians in 
Canada have been waiting years for this novel migraine and cluster headache therapy. 
RSK Medical Inc. is delighted to bring another breakthrough medical device technology to the Canadian marketplace. We look forward to working towards provincial healthcare funding for this patient group” said  Scott Kadwell, President of 
RSK Medical Inc.

“Migraine Canada is pleased to learn that a new device to treat migraine and cluster headaches has been approved by 
Health Canada. Timely and equitable access to diverse and affordable treatment options and devices are essential for patients living with these painful and debilitating diseases” said Dr.  Elizabeth Leroux, president of the 
Canadian Headache Society and the founder and chair of Migraine Canada.

“We are pleased to achieve another significant regulatory milestone as we expand our global business,” said Iain Strickland, electroCore’s Vice President of European Operations. “We are looking forward to supporting the growth of our Canadian distribution partner, RSK Medical Inc.”

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About RSK Medical, Inc.

Headquartered in 
Ontario, 
RSK Medical Inc. brings a wealth of experience, knowledge and keen responsiveness as a medical device supplier and is dedicated to providing innovative and disruptive medical device technologies to the Canadian clinical and patient community.

For more information, visit www.rskmedical.com  

About Migraine Canada
Migraine 
Canada is an alliance of patients and health care providers working together to improve the lives of people living with migraine and other headache disorders in 
Canada, through awareness, support, education, advocacy and research

For more information, visit www.migrainecanada.org

About gammaCoreTM

gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. 

gammaCore is FDA cleared in 
the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the 
European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
gammaCore contraindications include but are not limited to:

  • Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  • Patients with a metallic device, such as a stent, bone plate or bone screw, implanted at or near the neck
  • Patients who are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

Safety and efficacy of gammaCore have not been evaluated in the following patients:

  • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  • Pediatric patients (less than 12 years of age)
  • Pregnant women
  • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the business, operating or financial impact of such studies; the commercial potential of nVNS generally and gammaCore in particular in 
Canada and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the 
SEC available at www.sec.gov.

Investors:
Rich CockrellCG Capital
404-736-3838
[email protected]

or

Media Contact:
Summer Diaz
electroCore
816-401-6333
[email protected]

Genprex (GNPX) – to Present at the 2021 Virtual Cell and Gene Meeting on the Mediterranean

Posted on by Admin


Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean

AUSTIN, Texas — (April 5, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Executive Vice President and Chief Operating Officer, Michael Redman, will present at the annual Cell & Gene Meeting on the Mediterranean, which will take place virtually April 6-9, 2021.

Event: 2021 Virtual Cell & Gene Meeting on the Mediterranean

Date: The conference will take place virtually Tuesday, April 6  – Friday, April 9

Time: Company presentations will be available to view on-demand throughout the entirety of the conference

Registration Link: https://alliancerm.swoogo.com/meetingonthemed2021

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mediterranean is a four-day virtual conference featuring more than 80 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies. The meeting also includes more than 50 panelists and featured speakers taking part in 13 in-depth sessions covering all aspects of cell and gene therapy commercialization.

Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Stringham at [email protected] and interested media should contact Kaitlyn Dupont at [email protected].

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. 

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of REQORSA™ immunogene therapy drug, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining any FDA approvals of REQORSA and our other potential product candidates including whether we receive necessary approvals to commence clinical trials or benefit from fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Genprex, Inc.
(877) 774-GNPX (4679)

Investor Relations
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
[email protected]

Media Contact
Genprex Media Relations
(877) 774-GNPX (4679) ext. #3
[email protected]

Capstone Turbine (CPST) – CEO To Discuss Recent Revenue Growth Trends At The Upcoming Noble Capital Markets’ Virtual Road Show

Posted on by Admin


Capstone Turbine CEO To Discuss Recent Revenue Growth Trends At The Upcoming Noble Capital Markets’ Virtual Road Show

 

VAN NUYS, CA / ACCESSWIRE / April 1, 2021 / Capstone Turbine Corporation (NASDAQ:CPST), the world’s leading manufacturer of clean energy technology microturbine systems, today announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for Tuesday, April 6, 2021.

The virtual road show will feature a corporate presentation from Capstone Turbine President and Chief Executive Officer Darren Jamison, followed by a question and answer session moderated by Noble Senior Research Analyst Michael Heim, highlighting questions submitted by the audience.

“I look forward to discussing our recent top line revenue growth with potential shareholders as we execute against our strategic Revenue Growth Strategy, which consists of a six-element initiative designed to drive top line annual revenue,” said Darren Jamison, President and Chief Executive Officer of Capstone Turbine.

“I expect that the new Biden administration will create positive momentum for green initiatives and companies like Capstone, as President Biden recently signed an executive order to rejoin the U.S. into the Paris climate accord, his first major action to tackle global warming. In addition, the President’s recently proposed infrastructure plan will most likely have a green building and sustainability element,” added Mr. Jamison.

The live broadcast of the virtual road show is scheduled for Tuesday, April 6, 2021, at 1 PM EDT. Registration is free and open to all investors, at any level. Register Here.

Noble’s research, as well as news and advanced market data on Capstone Turbine is available on Channelchek.

About Capstone Turbine Corporation
Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) is the world’s leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup via our direct sales team, as well as our global distribution network. Capstone provides scalable solutions from 30 kWs to 10 MWs that operate on a variety of fuels and are the ideal solution for today’s multi-technology distributed power generation projects.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: [email protected]. To date, Capstone has shipped nearly 10,000 units to 83 countries and in FY20, saved customers an estimated $219 million in annual energy costs and 368,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, Facebook and YouTube.

About Noble Capital Markets
Noble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC / FINRA registered broker-dealer, dedicated exclusively to serving underfollowed small / microcap companies through investment banking, wealth management, trading & execution, and equity research activities. Over the past 36 years, Noble has raised billions of dollars for these companies and published more than 45,000 equity research reports. www.noblecapitalmarkets.com email: [email protected]

About Channelchek
Channelchek (.com) is a comprehensive investor-centric portal – featuring more than 6,000 emerging growth companies – that provides advanced market data, independent research, balanced news, video webcasts, exclusive c-suite interviews, and access to virtual road shows. The site is available to the public at every level without cost or obligation. Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC / FINRA registered broker-dealer since 1984. channelchek.vercel.app email: [email protected]

Cautionary Note Regarding Forward-Looking Statements
This release and the Company’s presentation and responses to questions at the Noble Capital Markets’ Virtual Road Show contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the generation of improvement in gross margin and expense absorption and other statements regarding expectations, beliefs, plans, intentions and strategies of the Company. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events, or for any other reason. “Capstone” and “Capstone Microturbine” are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT:
Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628
[email protected]

SOURCE: Capstone Turbine Corporation

How Fast are People Cutting the Cable Cord?

Posted on by Admin

 


Cord-Cutters, Advertisers, and Market Disruption

 

Internet television, or streaming TV, reached a tipping point last year. Viewers had more time at home to review the alternatives to cable and perhaps less money to pay for the cable subscription. This is only part of the reason why a full 15 percent of U.S. cable TV consumers cut the cord amid the pandemic-imposed lifestyle in 2020.

The number of subscribers to more traditional TV is fading just as the use of telephone landline customers faded after cell phones were adopted. And the change is happening quickly. The growth of TV viewers connected via streaming services grew to 84 million U.S. households according to eMarketer, while report fewer than 78 million U.S. households maintained a cable subscription by January 2021. This is causing accelerated disruption in spending on advertising. And the trend is unlikely to reverse. According to new research by TradeDesk and YouGov, the number of additional viewers who expect to cut the cord and be cable-free during 2021 is 27% which is an accelerated pace from the large 15% migration in 2020.

Subscriber Cost

Price is one of the factors driving this disruptive shift, but with untethered accessibility, fine-tuned selection, and the inclusion of traditional broadcasters offering online access, consumers can now opt for premium content they can watch where they want and on-demand. There is no longer a distinct prime time for viewing or advertisers, only prime shows.

Marketers acknowledge the rise of CTV and, as important, the move from linear TV. But, there still may be a heavier weighting toward ad spending on traditional TV relative to how the desired audience actually consumes news, sports, and entertainment. According to the TradeDesk report (The CTV Tipping Point), data indicates budgets are not yet fully allocated to where the target audience is most likely to be found. They reported that this is most prevalent for brands trying to reach a young audience. These brands are likely missing opportunities to reach potential customers who are no longer linked via a cable box. Despite the less than nimble shift, TradeDesk reports 89 percent of marketers believe that CTV advertising is just as, or more effective as linear TV. Each Spring a TV ad buying extravaganza named Upfronts is held where TV ad buyers and sellers hammer out billions in marketing agreements. At the most recent Upfronts, a majority (59 percent) of linear TV ad buyers said they’re making fewer upfront commitments in 2021, as the advertising industry is realigning to put their products on the screens of the right people.  One significant finding in the TradeDesk report is marketers’ preference for CTV to build awareness of their brands. Forty-three percent identified CTV as the number one channel for brand storytelling in 2021. The next best for introducing a brand was social media (29 percent), and then linear TV (26 percent).

Sports Impact

Live sports broadcasting is a factor helping to shift traditional activity among both advertisers and consumers. Live sports had been a key selling point keeping consumers attached to linear television. This is important because access to watch live sporting events has often been cited as a primary reason consumers continue to keep their cable subscriptions. However, the pandemic may have altered this as many viewers went without many major sporting events in 2020. Since then, as sports slowly return to traditional channels, audiences haven’t been following suit.

 

 

Advertisements

Many have migrated to new ways of watching live sports, including streaming and social. As a result of these shifts, TV marketers are adjusting their creative approach to take advantage of the benefits of CTV, which differ from the norms of linear TV. This has caused brands to develop new types of creative ads tailored for separate audiences.  According to the TradeDesk report, Ads are getting shorter, given that, the viewing experience on CTV differs from its linear counterpart. Additionally, marketers are also using more animation to prepare in case adjustments need to be made after the initial production.

Take-Away

Almost 50 percent of those who already have or plan to cut the cable cord say their main reason is that cable is too expensive. They just don’t feel they’re getting enough value with the service.  At the same time, more and more people are attracted to streaming services because they prefer the viewing experience and on-demand, where and when they’re ready. At present, about half of TV viewers say they still subscribe to cable TV services. Demographically the transition is being driven by more than the under-35 years-of-age population, 20 percent of cable subscribers 55 and older said they plan to cut the cord too.  

Once the cord is severed, and viewers adapt to the new services, they aren’t likely to return. Almost 79 percent of people who stopped paying for cable or never had it say they are unlikely to retain the service.

For investors, this growing shift to streaming means there could be opportunities in companies that provide streaming and ancillary services. Also, media companies to review to make see if they are changing as the world requires the new technology. Outside of the media industry, brands not reaching their intended audience with advertising may suffer as that could be a big differentiator between one brand and another with a similar product offering.

Suggested Reading:

Seeking Alpha Paywall Causes Frustration

Small Cap Names in a Big Crypto Market



Is it Smart to Avoid Brokers that Sell Order Flow?

Who Benefits from the American Jobs Plan?

 

Sources:

https://pages.thetradedesk.com/rs/527-INM-364/images/TheCTVTippingPoint_WhitePaper_TTD_Jan2021.pdf

https://digiday.com/marketing/upfrontses-wtf-upfronts/

https://www.fastcompany.com/90444295/the-major-battle-of-the-2020-streaming-wars-will-be-over-ads

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Capstone Turbine (CPST) – CEO To Discuss Recent Revenue Growth Trends At The Upcoming Noble Capital Markets Virtual Road Show

Posted on by Admin


Capstone Turbine CEO To Discuss Recent Revenue Growth Trends At The Upcoming Noble Capital Markets’ Virtual Road Show

 

VAN NUYS, CA / ACCESSWIRE / April 1, 2021 / Capstone Turbine Corporation (NASDAQ:CPST), the world’s leading manufacturer of clean energy technology microturbine systems, today announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for Tuesday, April 6, 2021.

The virtual road show will feature a corporate presentation from Capstone Turbine President and Chief Executive Officer Darren Jamison, followed by a question and answer session moderated by Noble Senior Research Analyst Michael Heim, highlighting questions submitted by the audience.

“I look forward to discussing our recent top line revenue growth with potential shareholders as we execute against our strategic Revenue Growth Strategy, which consists of a six-element initiative designed to drive top line annual revenue,” said Darren Jamison, President and Chief Executive Officer of Capstone Turbine.

“I expect that the new Biden administration will create positive momentum for green initiatives and companies like Capstone, as President Biden recently signed an executive order to rejoin the U.S. into the Paris climate accord, his first major action to tackle global warming. In addition, the President’s recently proposed infrastructure plan will most likely have a green building and sustainability element,” added Mr. Jamison.

The live broadcast of the virtual road show is scheduled for Tuesday, April 6, 2021, at 1 PM EDT. Registration is free and open to all investors, at any level. Register Here.

Noble’s research, as well as news and advanced market data on Capstone Turbine is available on Channelchek.

About Capstone Turbine Corporation
Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) is the world’s leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup via our direct sales team, as well as our global distribution network. Capstone provides scalable solutions from 30 kWs to 10 MWs that operate on a variety of fuels and are the ideal solution for today’s multi-technology distributed power generation projects.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: [email protected]. To date, Capstone has shipped nearly 10,000 units to 83 countries and in FY20, saved customers an estimated $219 million in annual energy costs and 368,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, Facebook and YouTube.

About Noble Capital Markets
Noble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC / FINRA registered broker-dealer, dedicated exclusively to serving underfollowed small / microcap companies through investment banking, wealth management, trading & execution, and equity research activities. Over the past 36 years, Noble has raised billions of dollars for these companies and published more than 45,000 equity research reports. www.noblecapitalmarkets.com email: [email protected]

About Channelchek
Channelchek (.com) is a comprehensive investor-centric portal – featuring more than 6,000 emerging growth companies – that provides advanced market data, independent research, balanced news, video webcasts, exclusive c-suite interviews, and access to virtual road shows. The site is available to the public at every level without cost or obligation. Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC / FINRA registered broker-dealer since 1984. www.channelchek.com email: [email protected]

Cautionary Note Regarding Forward-Looking Statements
This release and the Company’s presentation and responses to questions at the Noble Capital Markets’ Virtual Road Show contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the generation of improvement in gross margin and expense absorption and other statements regarding expectations, beliefs, plans, intentions and strategies of the Company. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events, or for any other reason. “Capstone” and “Capstone Microturbine” are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT:
Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628
[email protected]

SOURCE: Capstone Turbine Corporation

Release – Genprex (GNPX) – to Present at the 2021 Virtual Cell and Gene Meeting on the Mediterranean

Posted on by Admin


Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean

AUSTIN, Texas — (April 5, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Executive Vice President and Chief Operating Officer, Michael Redman, will present at the annual Cell & Gene Meeting on the Mediterranean, which will take place virtually April 6-9, 2021.

Event: 2021 Virtual Cell & Gene Meeting on the Mediterranean

Date: The conference will take place virtually Tuesday, April 6  – Friday, April 9

Time: Company presentations will be available to view on-demand throughout the entirety of the conference

Registration Link: https://alliancerm.swoogo.com/meetingonthemed2021

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mediterranean is a four-day virtual conference featuring more than 80 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies. The meeting also includes more than 50 panelists and featured speakers taking part in 13 in-depth sessions covering all aspects of cell and gene therapy commercialization.

Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Stringham at [email protected] and interested media should contact Kaitlyn Dupont at [email protected].

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. 

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of REQORSA™ immunogene therapy drug, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining any FDA approvals of REQORSA and our other potential product candidates including whether we receive necessary approvals to commence clinical trials or benefit from fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Genprex, Inc.
(877) 774-GNPX (4679)

Investor Relations
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
[email protected]

Media Contact
Genprex Media Relations
(877) 774-GNPX (4679) ext. #3
[email protected]

Release – electroCore Inc. (ECOR) – Announces Regulatory Approval in Canada

Posted on by Admin


electroCore, Inc. Announces Regulatory Approval in Canada

 

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that 
Health Canada has granted regulatory approval for the promotion and sale of the gammaCore Sapphire family of products in 
Canada for prevention and therapeutic treatment of migraine and cluster headache, as outlined in the registration application with 
Health Canada.

gammaCore Sapphire will be distributed in 
Canada by 
RSK Medical Inc., pursuant to an exclusive distribution agreement announced on 
January 26, 2021. The initial term of the agreement is three years, and the agreement contains customary terms and conditions, including minimum purchase commitments. “Patients and clinicians in 
Canada have been waiting years for this novel migraine and cluster headache therapy. 
RSK Medical Inc. is delighted to bring another breakthrough medical device technology to the Canadian marketplace. We look forward to working towards provincial healthcare funding for this patient group” said  Scott Kadwell, President of 
RSK Medical Inc.

“Migraine Canada is pleased to learn that a new device to treat migraine and cluster headaches has been approved by 
Health Canada. Timely and equitable access to diverse and affordable treatment options and devices are essential for patients living with these painful and debilitating diseases” said Dr.  Elizabeth Leroux, president of the 
Canadian Headache Society and the founder and chair of Migraine Canada.

“We are pleased to achieve another significant regulatory milestone as we expand our global business,” said Iain Strickland, electroCore’s Vice President of European Operations. “We are looking forward to supporting the growth of our Canadian distribution partner, RSK Medical Inc.”

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About RSK Medical, Inc.

Headquartered in 
Ontario, 
RSK Medical Inc. brings a wealth of experience, knowledge and keen responsiveness as a medical device supplier and is dedicated to providing innovative and disruptive medical device technologies to the Canadian clinical and patient community.

For more information, visit www.rskmedical.com  

About Migraine Canada
Migraine 
Canada is an alliance of patients and health care providers working together to improve the lives of people living with migraine and other headache disorders in 
Canada, through awareness, support, education, advocacy and research

For more information, visit www.migrainecanada.org

About gammaCoreTM

gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. 

gammaCore is FDA cleared in 
the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the 
European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
gammaCore contraindications include but are not limited to:

  • Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  • Patients with a metallic device, such as a stent, bone plate or bone screw, implanted at or near the neck
  • Patients who are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

Safety and efficacy of gammaCore have not been evaluated in the following patients:

  • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  • Pediatric patients (less than 12 years of age)
  • Pregnant women
  • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the business, operating or financial impact of such studies; the commercial potential of nVNS generally and gammaCore in particular in 
Canada and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the 
SEC available at www.sec.gov.

Investors:
Rich CockrellCG Capital
404-736-3838
[email protected]

or

Media Contact:
Summer Diaz
electroCore
816-401-6333
[email protected]

Release – CanAlaska Uranium (CVVUF)(CVV:CA) – CanAlaska Change to Board

Posted on by Admin


CanAlaska Change to Board
Victor Fern to go to new role with Cameco and Orano
CanAlaska address change

 

Vancouver, Canada, April 5, 2021 – CanAlaska Uranium Ltd.
(TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) (“CanAlaska” or the “Company”) reports that Victor Fern has resigned from the CanAlaska Board to pursue a new community role supporting Cameco and Orano’s operations in the Athabasca Basin. CanAlaska’s Management and Board of Directors wish Victor well in this new community role, and wishes to acknowledge the strong supporting role Victor has had with the direction of the Company’s activities since his appointment in 2008.

At the time of his appointment in March 2008 Mr Victor Fern was the immediate past Chief of the Fond du Lac Denesuline First Nation, at Fond du Lac, Saskatchewan. Mr Fern has been a longstanding member of the environmental monitoring committee for the Northern Athabasca area, and is involved with various private business interests in the Fond du Lac-Black Lake area. His extensive experience at uranium mining and milling operations in Northern Saskatchewan, and his 13 year tenure on the CanAlaska board makes him well suited to his new role as an advisor and educator in the community.

CanAlaska President, Peter Dasler, comments, “It has been a pleasure to work with Victor for the past 14 years, and to meet his friends and community. His new Community Liaison responsibilities for Cameco and Orano highlight how well regarded and knowledgeable is Victor. We can all learn a lot from each other, and I look forward to continuing our friendship and interactions in multiple matters into the future. Thank you Victor, best wishes from me and CanAlaska’s Board.”

Other News

 CanAlaska is moving to new offices in our current building. The new office address is Suite 580, 625 Howe Street, Vancouver, BC. V6C 2T6. This address will take effect May 1 2021.

About CanAlaska Uranium

 CanAlaska Uranium Ltd. (TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) holds interests in approximately 214,000 hectares (530,000 acres) in Canada’s Athabasca Basin – the “Saudi Arabia of Uranium.” CanAlaska’s strategic holdings have attracted major international mining companies. CanAlaska is currently working with Cameco and Denison at two of the Company’s properties in the Eastern Athabasca Basin. CanAlaska is a project generator positioned for discovery success in the world’s richest uranium district. The Company also holds properties prospective for nickel, copper, gold and diamonds. For further information visit www.canalaska.com.

The qualified technical person for this news release is Dr Karl Schimann, P. Geo, CanAlaska director and VP Exploration.

 

On behalf of the Board of Directors

 

“Peter Dasler”

Peter Dasler, M.Sc., P.Geo.

President & CEO

CanAlaska Uranium Ltd.

 

Contacts:

 

Peter Dasler, President

Tel: +1.604.688.3211 x 138

Email: [email protected]

 

Cory Belyk, COO

Tel: +1.604.688.3211 x 138

Email: [email protected]

 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.  

 Forward-looking information

 All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Source: CanAlaska Uranium Ltd.

Release – Kratos Defense and Security Solutions (KTOS) – Wins $86 Million U.S. Army Contract

Posted on by Admin


Kratos Wins $86 Million, Assuming All Options Exercised, Single Award U.S. Army Contract for Drone Command and Control Systems

 

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a leading National Security Solutions provider and industry-leading provider of high-performance unmanned systems, today announced that Micro Systems, Inc., a wholly owned subsidiary of Kratos Defense & Security Solutions, Inc. and part of the Kratos Unmanned Systems Division, has received an $85,949,472 contract award, with a $60.7M base and two options totaling approximately $25.3M, from the U.S. Army to support the Army Ground Aerial Target Control System, including software updating, cyber security inspections and installation of replacement parts.

Steve Fendley, President of Kratos Unmanned Systems Division, said, “We are incredibly excited about this substantial win for the Unmanned Systems Division and for Kratos overall. This enables us to evolve, develop, and apply new technologies to the UAS / UGV command and control systems for the Army, which support development, testing, and training associated with our country’s defensive systems and military personnel. Our ground-based infrastructure capability, the foundation for this contract, is key to our overall unmanned vehicle strategy to design, develop, and produce the entire system. Kratos is fully committed to developing affordable technologies and proud that these systems are employed to enable our troops and defensive systems to remain at the highest level of capability and readiness.”

Micro Systems, Inc. has been the primary designer, manufacturer, and supplier of high-performance unmanned aerial and ground target command and control systems to the U.S. Department of Defense since 1985. These hardware and software systems have provided reliable and robust capability successfully supporting over 3,000 operational weapon system test, training, and evaluation missions worldwide. Advanced features enabling multi-domain multi-vehicle mission profiles, remote and autonomous control modes, high-speed high bandwidth datalink communications, and ensured integrity with rigorous cybersecurity and Information Assurance (IA) implementations have made Micro Systems, Inc. the premier target control system provider for aerial (subscale, full scale, and rotary wing), ground, seaborne, and small unmanned aerial system (sUAS) platforms.

Kratos Unmanned Systems Division is a leading provider of high performance unmanned aerial drone and target systems for threat representative target missions to exercise weapon, radar, and other systems; and tactical aerial drone systems for strike/ISR and force multiplication missions.

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology, and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information, please visit www.KratosDefense.com.

Notice Regarding Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687

[email protected]

Source: Kratos Defense & Security Solutions, Inc.

Who Benefits from the American Jobs Plan?

Posted on by Admin

 


Industries that Could Benefit from the New “American Jobs Plan”

 

The $2 trillion American Jobs Plan proposed by the U.S. President to address a broad list of infrastructure projects was presented last week. The plan is structured to be financed over 15 years by jacking up taxes by 33.3% on corporations. If adopted, after first being considered, altered, and voted on by the legislative branch, investors can expect a substantial impact on the winners and losers from such a massive amount of money redirected from some companies and distributed selectively based on any final plan.

Taxes

As proposed, the non-Covid related plan with the stated purpose of helping workers has a price tag of $2 trillion over eight years. The designers anticipate raising corporate taxes to 28% from 21% and increasing taxes on business done outside the U.S. One main impact is raising the legal tax rate on business profits.

The increase in the statutory tax rate on domestic corporate income would be targeted at companies with business exposure within the U.S. that are paying close to 21% now. These are the businesses that led the economic boom after benefitting from the 2017 corporate tax cuts. The sectors that this will touch the most include financial firms, industrial companies, and many consumer-oriented firms with sales primarily in the U.S.

As far as business sectors with a high global presence, and therefore at targeted for higher taxes on foreign profits, technology can be expected to experience higher tax burdens. The Health Care sector, primarily international drug, and device manufacturers have been major beneficiaries of low foreign profit taxes; this would be unwound under the present plan.

Spending

Sectors that would benefit from direct government spending if the plan is enacted are transportation and infrastructure. There is a carve-out of $447 billion in transportation infrastructure to repair highways, rebuild bridges, upgrade ports, airports, and transit systems. There is an additional $111 billion for drinking water-related infrastructure. Broadband internet would benefit from a $100 billion allocation for improving the reach of communication systems. Power generation, including “clean energy” and electric grid improvements, would receive $100 billion as currently proposed.

 

 

There is $300 billion tagged for revitalizing and strengthening the manufacturing supply chain, $180 billion for government-led advances in “critical” technology. More directly impacting consumers, the President’s proposal would spend $174 billion to further electric vehicles and $213 billion for “green” and “affordable” homes.

The increased taxes on companies would be funneled to traditional infrastructure investment, including industrial and materials companies, while the redirected wealth to environmental issues should increase government-led spending to renewable energy companies. Mining and other natural resource firms should benefit from the substantial material requirements for the movement toward more diverse energy sources, electric vehicles, and efficient homes.

Utilities stand to benefit from increased investment in water and cleaner energy infrastructure. Many communication services and technology firms will likely benefit from broadband improvement spending.

Take-Away

Channelchek can provide readers with research, analytics, news, and statistics on hundreds of small and microcap companies in the sectors mentioned above. Small companies that could potentially benefit from increased spending in; Basic Materials, Communication, Government-funded dredging, Forest Products, Transportation, and Technology, can be found starting here.

The legislative process is fluid, and the spending and tax plans could change in the coming months. Keep in touch with us for updates as Washington moves closer to a final plan.

 

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading:

How Much is a Trillion?

Are Inflation and Interest Rates Expected to Rise?




Managing Investment Portfolio Risk

Stimulus Checks, Taxes, and Investments


Stay up to date. Follow us:

           


Stay up to date. Follow us: